Doer Biologics Doses First Patient In Ph 2 DR10624 Study
30 Sep 2024 //
PR NEWSWIRE
Zhejiang Completes Enrollment of Phase 1b/2a Trial Evaluating DR10624 in Obese
05 Jul 2024 //
PR NEWSWIRE
Doer Announces First Subject Dosed in MAD Trial of DR10624
01 Aug 2023 //
PR NEWSWIRE